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Reprogramming to induced pluripotent stem cells (iPSCs) proceeds in a stepwise manner with
reprogramming factor binding, transcription, and chromatin states changing during transitions.
Evidence is emerging that epigenetic priming events early in the process may be critical for pluri-
potency induction later. Chromatin and its regulators are important controllers of reprogramming,
and reprogramming factor levels, stoichiometry, and extracellular conditions influence the
outcome. The rapid progress in characterizing reprogramming is benefiting applications of iPSCs
and is already enabling the rational design of novel reprogramming factor cocktails. However,
recent studies have also uncovered an epigenetic instability of the X chromosome in human iPSCs
that warrants careful consideration.Decades of research were dedicated to studies of cell fate
changes during development and led to the view that, in vivo,
differentiated cells are irreversibly committed to their fate.
However, reprogramming of somatic cells by transfer into
enucleated oocytes pioneered by John Gurdon and colleagues
in the 1950s (Gurdon et al., 1958), fusion with other cell partners
(Blau et al., 1983), and ectopic transcription factor expression
(Davis et al., 1987; Takahashi and Yamanaka, 2006) revealed
a remarkable plasticity of the differentiated state. Particularly
the exposure to ectopic transcription factors offers a powerful
and unexpectedly flexible technique to shift a somatic cell
toward alternative somatic identities or pluripotency. The
reprogramming field exploded after Takahashi and Yamanaka
established a major landmark with the generation of induced
pluripotent stem cells (iPSCs) from fibroblasts by simple ectopic
expression of Oct4 (O), Sox2 (S), cMyc (M), and Klf4 (K) (Taka-
hashi and Yamanaka, 2006). Aptly, the Nobel Prize awarded to
John Gurdon and Shinya Yamanaka in 2012 symbolizes the
extraordinary contribution that reprogramming experiments
have made (and will make) to our understanding of cellular iden-
tity and the apparently unlimited practical applications of iPSCs
and other reprogrammed cells.
This Review focuses on reprogramming to iPSCs. The beauty
of transcription-factor-induced reprogramming to iPSCs lies in
its simplicity and robustness, as many different cell types from
a wide range of species can be reprogrammed to pluripotency
by ectopic expression of OSKM (for a recent summary, see
Stadtfeld and Hochedlinger [2010]). A fundamental feature of
the resulting iPSCs is that they are, in their ideal state, function-
ally indistinguishable from embryonic stem cells (ESCs), which
are pluripotent cells derived from preimplantation embryos,1324 Cell 152, March 14, 2013 ª2013 Elsevier Inc.and are capable of differentiation into cells of all three germ
layers (Bock et al., 2011; Carey et al., 2011). Consequently, re-
programming changes the transcriptome and chromatin state
of the somatic cell to that of a pluripotent cell (Chin et al.,
2009; Hawkins et al., 2010; Lister et al., 2011; Maherali et al.,
2007; Mikkelsen et al., 2008; Okita et al., 2007; Takahashi and
Yamanaka, 2006; Wernig et al., 2007). Therefore, iPSCs offer
an invaluable source of patient-specific pluripotent stem cells
for disease modeling, drug screening, toxicology tests, and
regenerative medicine (recently reviewed in Onder and Daley
[2012]; Trounson et al., 2012), and already have been employed
to unmask novel insights into human diseases (Koch et al., 2011).
Despite the extraordinary fidelity of the iPSC technology, the
induction of pluripotency upon OSKM expression typically
requires an extended latency period of around 1–2 weeks and
occurs in less than 1% of the starting cells, even when they are
genetically identical and the expression levels of the four tran-
scription factors are similar across all cells in the culture dish
(for a review, see Stadtfeld and Hochedlinger [2010]). Although
heterogeneity of the starting cell population and differentiation
state may affect reprogramming efficiency to a certain degree
(Stadtfeld and Hochedlinger, 2010), a key question has been
why only a few of a pool of seemingly equivalent OSKM-express-
ing cells induce pluripotency. Genomic approaches, RNAi
screens, and simpler genetic methods, as well as emerging
single-cell analyses, arebeginning toprovideanswersbydefining
critical reprogramming events as well as regulators and epige-
netic properties that promote or hinder reprogramming transi-
tions, which we will focus on in the first part of this Review.
Particularly the activation of pluripotency genes appears
to present a formidable task for the reprogramming factors.
Generally, transcriptional activation begins with the binding of
transcription factors to distal enhancer and promoter elements,
which initiates the recruitment of coactivators and facilitates
the binding of the general transcription machinery and the
assembly of the RNA polymerase-II-containing preinitiation
complex (PIC) at the core promoter (Green, 2005). Transcription
factors can also promote steps in the transcription process
subsequent to PIC assembly (which is of interest for the reprog-
ramming factor cMyc) (Green, 2005). Importantly, the packaging
of DNA into nucleosomes affects all aspects of transcription,
from transcription factor binding to PIC formation and transcrip-
tional elongation (Beato and Eisfeld, 1997; Li et al., 2007). The
ability of transcription factors to bind their recognition elements
is further modulated by changes in chromatin structure,
including DNA methylation, histone modifications, histone vari-
ants, or ATP-dependent chromatin remodeling. Chromatin
therefore plays a critical role in the establishment of cell-type-
specific expression patterns and is responsible for the extreme
stability of a given cellular identity under physiological condi-
tions, ensuring the stable silencing of lineage-inappropriate
genes and restricting transcription factor action to only a subset
of their target motifs in the genome (Filion et al., 2010; Gaetz
et al., 2012). In differentiated cells, pluripotency loci therefore
appear to be in an unfavorable chromatin landscape for binding
by most transcription factors. However, we will discuss the
remarkable capability of reprogramming factors to engage
closed chromatin and induce extensive chromatin changes
early in reprogramming before anymajor transcriptional changes
take place, unmasking interesting parallels between reprogram-
ming and developmental processes and highlighting the power
of the OSKM reprogramming cocktail. Together, these recent
findings have transformed the iPSC system into a powerful
model for the dissection of mechanisms underlying cell fate tran-
sitions.
The reprogramming process is most scrutinized in the mouse
system, but studies of the induced pluripotent state have been
extensively performed for both mouse and human iPSCs. Most
likely due to the fact that conventional mouse and human iPSCs
represent different states of pluripotency, these cells differ
epigenetically, as highlighted by their X chromosome inactiva-
tion state. In the second part of this Review, we will discuss
a selection of recent studies that revealed an epigenetic insta-
bility of the inactive X chromosome in female human iPSCs, remi-
niscent of processes in human ESCs, and we will focus on the
implications of these findings for the utility of iPSCs.
Steps Leading to the iPSC State
The development of improved reprogramming techniques that
include homogeneous and inducible reprogramming factor
expression systems (summarized in Stadtfeld and Hochedlinger
[2010]) has enabled a more detailed view of the mechanism
underlying reprogramming despite the fact that only few starting
cells become iPSCs. Mouse embryonic fibroblasts are most
commonly used as a starting cell type for the dissection of the
reprogramming process due to the ease of culture and the possi-
bility of derivation from different genetic backgrounds and
mouse models. Current evidence argues that reprogramming
of these cells to iPSCs requires cell division (Hanna et al.,2009) and is a multistep process in which the successful induc-
tion of the pluripotent state entails the transition through sequen-
tial gene expression states (or intermediates) (Figure 1). Failure to
transition through any of these steps would lead to a block in
reprogramming and would account for the low overall reprog-
ramming efficiency. Consistent with this model, it was shown
early on by the Jaenisch and Hochedlinger groups that reprog-
ramming cultures represent heterogeneous cell populations
that can be resolved based on the expression of cell surface
markers (Brambrink et al., 2008; Stadtfeld et al., 2008). Utilizing
specific surface marker combinations, cells poised to become
iPSCs can be enriched at different times of reprogramming.
This knowledge allowed the inference of a reprogramming path
in which successfully reprogramming cells first downregulate
the fibroblast-associated marker Thy1 and then transition to
a state that is positive for the embryonic marker SSEA1 and,
finally, induce the full pluripotency network (Brambrink et al.,
2008; Polo et al., 2012; Stadtfeld et al., 2008) (Figure 1). The
downregulation of Thy1 occurs in a large fraction of starting cells,
the subsequent gain of SSEA1 only in a subset of Thy1-negative
cells, and the induction of the pluripotency network in a small
subset of SSEA1-positive cells, indicating that transitions
between each of these steps occurwith lowprobability (Figure 1).
Cells that are unable to silence Thy1 relatively quickly upon
OSKM expression become refractory to the action of the reprog-
ramming factors and can yield iPSCs though with dramatic delay
and at much lower efficiency (Polo et al., 2012). Accordingly,
a single-cell cloning experiment demonstrated that virtually all
starting cells have the potential to induce pluripotency in a small
subset of their daughter cells when reprogramming is followed
over a 6 month period (Hanna et al., 2009). The intermediate
states defined by cell sorting experiments likely represent the
most favored possibilities on the path of reprogramming. Further
purification of reprogramming intermediates should be feasible
and provide insight into whether all reprogramming cells have
to pass through the same stages to induce pluripotency. Of
interest, SSEA1-positive intermediate cells are still plastic early
in reprogramming in that some of these cells can regress to
the Thy1-positive (i.e., an earlier) reprogramming state in the
presence of reprogramming factor expression. By contrast, later
in reprogramming, these cells appear to have matured and
becomemuchmore committed to progressing to the pluripotent
state (Polo et al., 2012), indicating that cellular identity is only
stabilized and locked in toward the end of the reprogramming
process.
Genome-wide transcriptional profiling was used to further
delineate the sequence of events that drive reprogramming.
Initially, cells appear to respond relatively homogeneously to
the expression of the reprogramming factors (Polo et al.,
2012) and robustly silence typical mesenchymal genes ex-
pressed in fibroblasts (such as Snai1, Snai2, Zeb1, and
Zeb2) (Li et al., 2010; Mikkelsen et al., 2008; Polo et al., 2012;
Samavarchi-Tehrani et al., 2010). These events lead to the acti-
vation of epithelial markers (such as Cdh1, Epcam, and Ocln) in
a process called mesenchymal-to-epithelial transition (MET),
which seems critical for the early reprogramming phase and is
accompanied by morphological changes, increased prolifera-
tion, and the formation of cell clusters (Li et al., 2010; MikkelsenCell 152, March 14, 2013 ª2013 Elsevier Inc. 1325
Figure 1. The Generation of iPSCs Is a Multistep Process that Can Be Modulated by Extracellular Cues and Reprogramming Factor Levels
Known events occurring in early, middle, and late phases during the OSKM-mediated reprogramming of mouse embryonic fibroblasts to iPSCs are depicted.
During the final emergence of fully reprogrammed iPSCs, so-called ‘‘reprogramming-competent cells’’ appear to be inhibited by the continued expression of the
factors. The reprogramming process can be preferentially trapped in partially reprogrammed states when certain reprogramming factor levels and/or stoichi-
ometries are employed (top) or can be redirected to a different cell identity, without going through the pluripotent state, by changing culture/growth factor
conditions and timing of OSKM expression (bottom).et al., 2008; Samavarchi-Tehrani et al., 2010; Smith et al., 2010).
Notably, the aforementioned transition to the SSEA1-positive
state appears to correlate with the occurrence of MET (Polo
et al., 2012; Samavarchi-Tehrani et al., 2010) (Figure 1). The
key characteristic of subsequent reprogramming phase is the
gradual activation of pluripotency-associated genes (Brambrink
et al., 2008; Buganim et al., 2012; Golipour et al., 2012;
Mikkelsen et al., 2008; Polo et al., 2012; Samavarchi-Tehrani
et al., 2010; Sridharan et al., 2009; Stadtfeld et al., 2008). For
example, the pluripotency loci Nanog and Sall4 are transcrip-
tionally upregulated at a late intermediate stage, whereas
others, such as Utf1 or endogenous Sox2, are induced even
later, closely mirroring the acquisition of the full pluripotency
expression programming (Figure 1). Although detailed time
course studies describing these transitions in reprogramming
cells still need to be performed at the single-cell level, a recent
single-cell expression study that compared the expression of
candidate genes at various reprogramming stages strongly
supports a series of consecutive pluripotency gene activation
steps late in the reprogramming process (Buganim et al.,
2012). Together, these events culminate in the establishment
of the pluripotent state that can be sustained independently of
ectopic reprogramming factor expression (Brambrink et al.,
2008; Maherali et al., 2007; Okita et al., 2007; Stadtfeld et al.,
2008; Wernig et al., 2007).1326 Cell 152, March 14, 2013 ª2013 Elsevier Inc.Modifying the Reprogramming Process
Early studies employing inducible reprogramming factor ex-
pression systems indicated that reprogramming intermediates
are dependent on continued OSKM expression to complete
the reprogramming process (Brambrink et al., 2008; Stadtfeld
et al., 2008). In addition, evidence is growing that the efficiency
of reprogramming is strongly influenced by the levels of the re-
programming factors. For example, fibroblasts engineered to
express a higher dose of OSKM in all cells have a dramatically
enhanced ability to induce pluripotency (Polo et al., 2012). A
peculiar observation is that cells that become refractory to re-
programming early on (and stay Thy1 positive) have dramatically
reduced protein levels of the four reprogramming factors
compared to cells that are able to progress toward pluripotency
(Polo et al., 2012). Because the RNA levels of the reprogramming
factors are similar between these two cell populations, these
transcription factors may be prone to increased ubiquitination
and degradation specifically in refractory cells (Buckley et al.,
2012; Polo et al., 2012). Furthermore, the inability to sustain
high reprogramming factor expression contributes strongly to
the reprogramming block in refractory cells, as a further increase
in OSKM expression specifically in these cells induces them to
convert to the next reprogramming stage and subsequently to
iPSCs more efficiently (Polo et al., 2012). Although continuity of
reprogramming factor expression is essential for driving somatic
cells toward pluripotency, a recent study pointed out that high
levels of ectopic OSKM during the final reprogramming steps
may be inhibitory to the efficient induction of the full pluripotency
network (Golipour et al., 2012) (Figure 1). This finding is consis-
tent with the observations that retrovirally expressed reprogram-
ming factors are efficiently turned off in faithfully reprogrammed
cells (Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007)
and that the activation of endogenous pluripotency regulators
during reprogramming coincides with transgene independence
(Stadtfeld et al., 2008). The reduction of ectopic reprogramming
factors at the end of reprogramming may be necessary because
even a modest increase in Oct4 levels in ESCs is detrimental to
the pluripotent state (Niwa et al., 2000).
Not just overall levels and timing, but also the specific balance
of the reprogramming factors relative to each other are critical for
the outcome of reprogramming (Figure 1). For example, many
studies agree that high Oct4 levels and low levels of Sox2
increase the efficiency of reprogramming (Nagamatsu et al.,
2012; Tiemann et al., 2011; Yamaguchi et al., 2011). High Sox2
levels have been associated with the stronger induction of devel-
opmental markers during reprogramming, whichmay guide cells
away from the path to pluripotency (Yamaguchi et al., 2011).
Moreover, even though ectopic expression of cMyc enhances
reprogramming, it also leads to emergence of a large fraction
of partially reprogrammed ESC-like colonies trapped before
the upregulation of the pluripotency program (Nakagawa et al.,
2008; Wernig et al., 2008). Remarkably, differences in reprog-
ramming factor stoichiometry appear to have consequences
for the epigenetic state and developmental potential of the
resulting iPSCs (Carey et al., 2011). This is an interesting result
in light of the ongoing debate on epigenetic differences between
iPSCs and ESCs (for a recent discussion, see Lowry, [2012]) and
suggests that at least some (and maybe all) of the observed vari-
ations between iPSCs and ESCs are not inherent to the reprog-
ramming process but are due to experimental variables that
often are not easy to control, highlighting how a better under-
standing of the mechanisms underlying reprogramming will
benefit the production of safer iPSC lines.
The efficiency of iPSC formation can also be improved by
altering media composition and growth factor conditions (Chen
et al., 2011; Esteban et al., 2010; Ichida et al., 2009; Li et al.,
2010; Samavarchi-Tehrani et al., 2010). Though it is likely that
downstream effectors of signaling pathways directly alter the
transcriptional output of their target genes, specific culture
conditions can also modulate the activity and levels of chromatin
regulators, thereby indirectly affecting OSKM functionality (Chen
et al., 2013; Marks et al., 2012; Wang et al., 2011a; Zhu et al.,
2013). To mention just one example, vitamin C (ascorbic acid)
addition to the media increases reprogramming efficiency and
potentially the quality of resulting iPSCs at least in part by influ-
encing the functionality of histone demethylases that depend on
iron (Esteban et al., 2010; Stadtfeld et al., 2012; Wang et al.,
2011a).
Notably, by supplementing OSKM-reprogramming cultures
with a growth factor cocktail normally required for the establish-
ment and maintenance of epiblast stem cells (EpiSCs), mouse
fibroblasts can be reprogrammed to an EpiSC-like state instead
of the ESC-like iPSC state (Han et al., 2011) (Figure 1). MouseEpiSCs and ESCs capture two different states of pluripotency,
which will be discussed in greater detail in the second part of
this Review. During the last couple of years, it has also become
clear that OSKM (or a subset of these factors) can even prompt
the establishment of various somatic cell fates, including cardio-
myocytes, blood progenitors, and neural stem cells, when over-
expressed temporally and guided by appropriate extracellular
cues, without the transition through the pluripotent state
(Figure 1) (reviewed in Sancho-Martinez et al. [2012]). The induc-
tion of various developmental regulators at intermediate stages
of reprogramming to pluripotency may explain why OSKM can
efficiently redirect the reprogramming path to other cell identities
upon exposure to suitable signaling cues and likely reflects
a function of Sox2 and Klf4 as critical regulators of various differ-
entiation paths during development (Mikkelsen et al., 2008; Polo
et al., 2012; Sridharan et al., 2009). Alternatively, and not mutu-
ally exclusive, reprogramming intermediates arising due to
OSKM expression may represent normally occurring develop-
mental progenitor states. Though the picture is emerging that
signaling cues affect the cell fate choices made during reprog-
ramming and/or lead to the stabilization of particular cell identi-
ties that arise during the process, still relatively little is known
about the exact role of signaling pathways and their downstream
regulators in reprogramming and the intersection with the re-
programming factors. Comparing the molecular dynamics of
OSKM-dependent induction of pluripotency and alternative cell
fates should demonstrate how cell fate decision processes can
be efficiently modulated and will facilitate the development of
patient-specific somatic cell populations for clinical applications.
Defining the Target Repertoire of the Reprogramming
Factors
One approach toward a better understanding of the cascade of
molecular events underlying the establishment of pluripotency is
the definition of reprogramming factor targets at different stages
of the reprogramming process. It is generally believed that three
of the four reprogramming factors, Oct4, Sox2, and Klf4, are
necessary for the induction of pluripotency because they are
critical components of an intrinsic and highly stable pluripotency
network (Boyer et al., 2005; Chen et al., 2008; Jiang et al., 2008;
Kim et al., 2008; Loh et al., 2006; Sridharan et al., 2009). Oct4,
Sox2, and Klf4 tend to colocalize at many cell-type-specific
enhancers in ESCs, often together with additional pluripotency
transcription factors like Nanog, Esrrb, Klf2, Sall4, and Zfp42
and signaling pathway regulators such as Smad1 and Stat3
(Chen et al., 2008; Kim et al., 2008), reinforcing the importance
of OSK for the pluripotent state and the view that enhancers
are sentinels of cell-type-specific gene expression patterns (Vi-
sel et al., 2009). The integration of numerous pluripotency tran-
scription factors and signaling cues at these enhancers ensures
the expression of many genes with known roles in pluripotency
and provides stability to the ESC gene expression program.
Another important aspect of the pluripotency network is that
many pluripotency transcription factors constitute a transcrip-
tional circuit wired in a feed-forward type of regulation, as they
induce their own expression and positively regulate each other
(Boyer et al., 2005; Chen et al., 2008; Jiang et al., 2008; Kim
et al., 2008) (Figure 2A).Cell 152, March 14, 2013 ª2013 Elsevier Inc. 1327
Figure 2. Features of OSKM in ESCs and during Reprogramming
(A) In ESCs, Oct4, Sox2, and Klf4 bind their own and each others’ promoters and enhancers, as well as those of many additional ESC-specific (pluripotency)
genes. Further contributing to the pluripotency circuitry, many of these ESC-specific genes are also bound by various additional pluripotency regulators, including
Nanog and Esrrb, such that ESC-specific enhancers represent hot spots of pluripotency transcription factor binding.
(B) In ESCs (andmany other cell types), cMyc targetsmost actively transcribed genes at the core promoter by binding high-affinity E box sequences and functions
by enhancing transcriptional elongation. Expression levels correlate with cMyc occupancy. Upon overexpression, cMyc does not appear to regulate new target
genes but amplifies the existing gene expression pattern by binding the same genes at elevated levels and occupying additional, low-affinity E-box-like
sequences in both the core promoter and enhancer regions of these genes.
(C) Scheme illustrating different contributions of the reprogramming factors to the late phase of reprogramming, highlighting separable engagement of OSK
and cMyc. Many genes occupied by cMyc in ESCs/iPSCs are already bound by this transcription factor and are expressed in partially reprogrammed cells,
which represent a clonal, late reprogramming intermediate. By contrast, OSK bind the promoter regions of many of their ESC/iPSC-specific target genes only
late in reprogramming, accompanying their transcriptional upregulation. This is particularly obvious for those genes that are cobound by OSK in their promoter
region in ESCs.
(D) Chromatin can affect the ability of transcription factors to bind to their DNA motifs, which is thought to explain why most transcription factors bind to only a
small subset of their recognition motifs in the genome. Here, we summarize the chromatin preferences of the four reprogramming factors early in reprogramming.By contrast, cMyc is unique among the reprogramming
factors, as it is neither a component of the core pluripotency
network (Chen et al., 2008; Kim et al., 2010) nor absolutely
necessary for reprogramming to iPSCs (Nakagawa et al., 2008;
Wernig et al., 2008). Indeed, cMyc is a central player in many
diverse biological processes, including cell growth and differen-
tiation. Two recent reports (Lin et al., 2012; Nie et al., 2012)
strongly support a model in which cMyc is not a transcription
factor that is responsible for OFF/ON switches of its target genes
as proposed for OSK. Instead, cMyc is a nonlinear amplifier of
transcriptional outputs that acts universally on active genes con-
taining the E box DNA motif. Mechanistically, cMyc promotes
transcription by regulating RNA polymerase II pause-release
and by increasing the rate of transcriptional elongation (Rahl
et al., 2010). Therefore, cMyc occupies the core promoter
regions of many active genes in ESCs/iPSCs and is typically1328 Cell 152, March 14, 2013 ª2013 Elsevier Inc.not present at enhancers (Chen et al., 2008; Kim et al., 2010;
Nie et al., 2012; Soufi et al., 2012; Sridharan et al., 2009)
(Figure 2B). Analysis of cMyc binding across different inducible
expression levels in tumor cells demonstrated that cMyc
predominantly binds high-affinity E box sites at core promoters
of almost all active genes when expressed at low levels but spills
over to weaker E box sites within enhancers of the same active
genes upon higher expression, likely because promoter sites
become saturated (Figure 2B) (Lin et al., 2012; Nie et al., 2012).
Thus, the target repertoire of cMyc does not change when
cMyc is strongly expressed, but transcriptional output is
increased. The significant differences between OSK and cMyc
have important implications for the reprogramming process.
Oct4, Sox2, and Klf4 are probably crucial for specifying cell
fate change in reprogramming, whereas cMyc may simply act
by amplifying arising expression changes due to OSK action at
genes that contain E boxes, potentially helping to trap genes in
the ON state.
The low efficiency of reprogramming makes the application of
genome-wide analysis techniques of reprogramming factor
binding, such as chromatin immunoprecipitation combined
with massive parallel sequencing (ChIP-seq), challenging for
cells at intermediate stages of the reprogramming process. To
circumvent this problem, our lab initially mapped reprogramming
factor binding within promoter regions in iPSCs and in partially
reprogrammed cells—which represent a clonal, trapped late re-
programming intermediate expanded from ESC-like colonies
that arise in reprogramming cultures and fail to express pluripo-
tency regulators—and compared occupancy data with gene
expression patterns (Sridharan et al., 2009). In both cell types,
genes co-occupied by the reprogramming factors are highly ex-
pressed, indicating that an intrinsic property of reprogramming
factor cobinding is to activate genes. Interestingly, genes that
are more highly expressed in partially reprogrammed cells than
in ESCs are often more efficiently targeted by the OSKM factors
in the intermediate state than in ESCs, whereas genes more
highly expressed in ESCs are generally less bound in partially re-
programmed cells than in ESCs. Thus, many genes are more
strongly expressed in partially reprogrammed cells compared
to ESCs due to targeting of the four factors to promoter regions
that they do not normally bind in ESCs, and conversely, the
failure to activate ESC-specific genes appears to result from
the inability of the factors to bind these genes in the intermediate
state. These findings are consistent with the reprogramming
factors being directly responsible for the ‘‘ectopic’’ expression
of developmental genes in reprogramming intermediates, which
is known to hinder reprogramming (Mikkelsen et al., 2008).
Notably, the widespread lack of ESC-specific promoter binding
in partially reprogrammed cells impinges more dramatically on
Oct4, Sox2, and Klf4 than on cMyc and particularly affects
many pluripotency-related genes that are co-occupied by
combinations of Oct4, Sox2, and Klf4 in ESCs (Figure 2C). In
the case of these genes, it appears that the OSK promoter
engagement occurs only toward the very end of the reprogram-
ming process and is likely required for their transcriptional
activation (Figure 2C). These findings not only demonstrate
a separable contribution of cMyc and OSK to the activation of
various pluripotency loci and a change in the reprogramming
factor target repertoire during the reprogramming process, but
also indicate that the promoter engagement of key pluripotency
genes is a critical task for reprogramming.
Recently, Zaret and colleagues obtained a picture of the initial
chromatin engagement of the reprogramming factors by per-
forming ChIP-seq 48 hr after the induction of reprogramming
factor expression in human fibroblasts (Soufi et al., 2012),
when most cells still undergo very similar expression changes
(see above) (Polo et al., 2012). Comparing OSKM-binding
patterns between the early reprogramming stage and the plurip-
otent state, Zaret and colleagues made two interesting observa-
tions (Soufi et al., 2012). First, many more genes are bound by all
four factors early in reprogramming than in the pluripotent state,
which could be due to the high expression levels of the induced
factors. In addition, OSKM binding of apoptosis-regulating
genes early in the process suggests that the extensive cell deathapparent in reprogramming cultures (reviewed in Plath and
Lowry [2011]) is a direct consequence of reprogramming factor
binding, potentially representing a general cellular defense
mechanism against ectopic transcription factor expression
(Soufi et al., 2012). Furthermore, initial target genes of the re-
programming factors are significantly enriched for regulators of
MET, the critical early reprogramming event discussed above,
whereas pluripotency loci such as NANOG and DPPA4 are not
yet bound, corroborating that a redistribution of OSKM binding
occurs as cells move along the reprogramming path and sug-
gesting that, initially, the reprogramming factors directly target
at least some of the genes that transcriptionally change early in
the process. The second and more surprising finding is that
the reprogramming factors interact extensively with distal
genomic sites, including some known enhancers. Indeed, 85%
of all initial binding events occur distal to promoter regions (Soufi
et al., 2012). Because it appears that, in the pluripotent state, the
transcription factors have shifted to a binding pattern that
includes promoter regions much more strongly, Zaret and
colleagues proposed that the binding of the reprogramming
factors to distal elements is an early step in reprogramming
that precedes promoter binding and transcriptional activation
of many target genes (Soufi et al., 2012).
Reprogramming Factors as Pioneers
The next question then is which features anticipate the recruit-
ment of ectopically expressed OSKM? The DNA motifs of the
four factors are enriched at their respective binding sites, indi-
cating that they are recruited directly through their sequence
motifs rather than randomly targeting or scanning the genome
(Soufi et al., 2012; Sridharan et al., 2009). However, transcription
factors work in a concentration-dependent manner and will, at
higher concentration, also occupy DNA sites of lower affinity,
which may be important for reprogramming, during which very
high levels of ectopic OSKM are expressed (Lin et al., 2012;
Nie et al., 2012; Soufi et al., 2012) (Figure 2B). Notably, lineage
specification factors present in the starting cell type may
contribute to the targeting of the reprogramming factors to
a subset of their DNA motifs. For example, during lineage
development, Sox transcription factors often occupy sites pre-
marked by other Sox proteins that were expressed in the
previous developmental stage (Bergsland et al., 2011). If such
lineage-specific factors are involved in the initial targeting of
the reprogramming factors, one might predict that reprogram-
ming factors will target different genomic locations in different
starting cell types.
Importantly, chromatin is thought to strongly affect the ability
of transcription factors to bind their cognate DNA motifs, and
certain chromatin states, characterized for example by the pres-
ence of specific combinations of histone modifications, may be
especially conducive to DNA binding by specific transcription
factors (Filion et al., 2010). As expected, binding of the reprog-
ramming factors does occur in open and accessible chromatin,
marked by active histone modifications such as H3K4 methyla-
tion (Soufi et al., 2012; Sridharan et al., 2009) (Figure 2D). Among
the reprogramming factors, cMYC binding is much more strictly
associated with a pre-existing active chromatin state than that of
OSK (Soufi et al., 2012; Sridharan et al., 2009), which isCell 152, March 14, 2013 ª2013 Elsevier Inc. 1329
consistent with active chromatin being a prerequisite for the
binding of cMyc (Guccione et al., 2006) (Figure 2D). An aston-
ishing observation by Zaret and colleagues is that the vast
majority (around 70%) of reprogramming factor binding events
early in human fibroblast reprogramming occurs within genomic
regions that display a closed chromatin state in the starting fibro-
blasts characterized by the absence of DNase hypersensitivity
and, surprisingly, any histone modifications (Soufi et al., 2012).
Thus, the reprogramming factors can efficiently access their
target sequences within genomic regions that are packed with
nucleosomes and are probably even further condensed into
higher-order structures. This is particularly true for OSK and, to
a much lesser extent, for cMYC (Soufi et al., 2012) (Figure 2D).
Indeed, the ability of cMYC to access target sites in closed chro-
matin is dependent on OSK occupancy (Soufi et al., 2012). OSK
can occupy OSKM cobound sites in the absence of ectopic
cMYC, but cMYC cannot bind when overexpressed in the
absence of ectopic OSK. In turn, ectopic cMYC enhances the
initial binding of OSK to these sites when expressed together.
These data are in agreement with cMyc potentiating the action
of the other three reprogramming factors rather than initiating
these events.
In comparison to naked DNA, nucleosomal DNA is less acces-
sible for DNA-binding factors (Beato and Eisfeld, 1997), and the
majority of transcription factors cannot bind their cognate sites
when sequestered within a nucleosome and need a structural
change in the associated nucleosome or a nucleosome-free
region for binding (Wallrath et al., 1994), highlighting an impor-
tant functionality of OSK. Cooperative binding or simultaneous
engagement of neighboring binding sites could explain the ability
of OSK to interact with nucleosomal-binding sites (Adams and
Workman, 1995). For instance, binding of one factor might
partially destabilize a nucleosome, allowing the other transcrip-
tion factor(s) to access sites that were previously buried.
However, each of the OSK-reprogramming factors alone can
also target sites in closed chromatin, i.e., without the other two
factors being detected at those sites (Soufi et al., 2012). There-
fore, Zaret and colleagues proposed that Oct4, Sox2, and Klf4
each can act as pioneer factors that are able to access closed
chromatin on their own without the help of additional transcrip-
tion factors (Soufi et al., 2012). There is additional evidence in
support of this idea. First, based on three-dimensional (3D)
structures, Oct4, Sox2, and Klf4, but not cMyc, interact with
one side of the DNA helix when bound to DNA, potentially allow-
ing them to bind DNA in the context of the nucleosome (Beato
and Eisfeld, 1997; Soufi et al., 2012). Second, a comparison of
nucleosome occupancy with binding of Oct4 and Sox2 in
ESCs genome-wide suggests that Oct4 and Sox2 can, at least
in part, interact with nucleosomal DNA (Teif et al., 2012). Third,
Sp1, a transcription factor belonging to the same family of highly
related transcription factors as Klf4, can bind nucleosomal DNA
in vitro, making it reasonable to anticipate that Klf4 will share
SP1’s capacity (Li et al., 1994). Fourth, it was found that pre-
existing nucleosomes at the enhancer and promoter regions of
the OCT4 and NANOG gene loci are displaced when OCT4 is
ectopically expressed in differentiated cells (i.e., in the absence
of any other reprogramming factors) (You et al., 2011). This chro-
matin reorganization coincided with Oct4 binding, suggesting1330 Cell 152, March 14, 2013 ª2013 Elsevier Inc.that Oct4 is able to directly access DNA sites that are internal
to a nucleosome and establish a nucleosome-depleted region
(You et al., 2011).
The idea of OSK acting as pioneer factors in reprogramming
is exciting because it is reminiscent of developmental decisions,
wherein pioneer factor binding at enhancers occurs early (Gualdi
et al., 1996). The efficient activation of lineage-specific genes
during development often requires a cascade of DNA-transcrip-
tion factor interactions and chromatin changes at their enhancer
and promoter regions, which begin long before these genes are
transcribed (Zaret and Carroll, 2011). Pioneer transcription
factors initiate this series of events by accessing tissue-specific
enhancers already at a very early developmental stage and by
inducing chromatin decondensation, remodeling, and/or
a change in local chromatin modifications, thereby priming
enhancer and promoter regions for binding by additional tran-
scription factors and transcriptional activation at a later stage
of development. Thus, pioneer factors are initiator factors that
make regulatory regions competent for activation in response
to the right stimulus.
In the context of reprogramming, the binding of OSK to closed
chromatin early in reprogramming could therefore be a crucial
step for events that happen later in the process, particularly
considering that some of these distal binding events overlap
with known enhancers. One may speculate that Oct4, Sox2,
and Klf4 can engage at least some ESC-specific enhancers early
in reprogramming even though they are locked up in closed
chromatin in the starting fibroblasts, poising them for promoter
binding and transcriptional activation later in the process. In
the next section, we will provide additional evidence in support
of such epigenetic priming by focusing on chromatin changes
that occur early in the reprogramming process.
Chromatin Changes in Promoters and Enhancers Early
in Reprogramming
An analysis of the initial transcriptional and chromatin changes
early in mouse cell reprogramming (i.e., 24–72 hr after induction
of the reprogramming factors) revealed striking parallels to the
initial reprogramming factor binding pattern (Koche et al.,
2011). First, gene expression changes, both up and down, are
largely confined to genes with promoter regions carrying active
chromatin marks in the starting fibroblasts (i.e., in regions
marked by enrichment of H3K4me3, a modification associated
with the transcriptional start sites of active and poised genes)
(Koche et al., 2011). The restriction of expression changes to
genes that are already in an open and accessible chromatin
configuration is consistent with the fact that the perturbation of
the somatic gene expression program is the major response
early in the reprogramming process (Koche et al., 2011;
Mikkelsen et al., 2008; Polo et al., 2012; Samavarchi-Tehrani
et al., 2010; Sridharan et al., 2009).
Unexpectedly, changes in histone modifications are much
more widespread than initial changes in gene expression,
indicating that an extensive genome-wide chromatin remodeling
takes place as immediate response to reprogramming factor
expression (Koche et al., 2011). In addition to chromatin changes
associated with gene expression switches, H3K4me2 (a histone
mark associated with active or poised promoters and enhancers)
Figure 3. Chromatin Dynamics during Reprogramming
Many fibroblast-specific promoters and enhancers are decommissioned early in reprogramming (after 24–48 hr of reprogramming factor expression) by loss of
active H3K4 methylation marks but appear to gain DNA methylation only late in reprogramming. ESC-specific enhancers and promoters can be divided into at
least two groups: those with dramatic changes in histonemodifications already early in reprogramming, long before their transcriptional activation, and those that
undergo histone modification changes only much later in the process. One key difference between these groups appears to be the DNA methylation state. For
example, the first group includesmany pluripotency genes with CpG-dense promoter elements (indicated by higher density of circles) that are hypomethylated in
fibroblasts.rapidly emerges de novo in many promoter regions in the
absence of transcriptional changes and even before any cell divi-
sion has taken place (Figure 3). Many of these promoters belong
to genes that are transcriptionally activated later in reprogram-
ming, including various pluripotency regulators like Sall4,
Pecam1, FoxD3, and Lin28. The gain of H3K4me2 is not accom-
panied by simultaneous accumulation of the H3K4me3mark and
often occurs on a nucleosome that covers the transcriptional
start site. Because nucleosomes at transcriptional start sites
are incompatible with the assembly of the basic transcriptional
machinery (Lorch et al., 1987), nucleosome depletion must be
one of the subsequent steps that allows transactivation of these
genes later in reprogramming. Interestingly, promoters with
H3K4me2 gain early in reprogramming often display a high
CpG density and are enriched for CpG islands (Koche et al.,
2011) (Figure 3), which may obviate the need for extensive chro-
matin remodeling and therefore facilitate quick changes in chro-
matin structure due to lower nucleosome occupancy (Ramirez-
Carrozzi et al., 2009).
Compared to promoters, chromatin changes at enhancers are
even more prominent early in reprogramming (Koche et al.,
2011), which is consistent with the observations that many
enhancers are active in only a single cell type and that the chro-
matin state of enhancers is more variable across cells types than
that of promoters (Heintzman et al., 2009). The systematic
mapping of enhancers is now possible genome-wide because
specific enhancer-associated chromatin signatures have beenidentified that even reveal the activity of the enhancer (Creyghton
et al., 2010; Heintzman et al., 2009; Koche et al., 2011; Rada-
Iglesias et al., 2011). In the active state (i.e., when associated
with an actively transcribed gene), enhancer elements are
demarcated by domains of H3K27Ac and H3K4me1/me2, but
not H3K4me3. In association with inactive genes, enhancers
can be in one of two states: unmarked (i.e., inactive), lacking
all of the features that are associated with the active enhancer
state, or poised, carrying H3K4me1/me2 in the absence of
H3K27ac. It is thought that poised enhancers are important for
the plasticity of developmental decisions, as a subset can
acquire the signature of active enhancers upon change in
external stimuli. The specific enhancer state therefore appears
to strongly influence the ability of the cell to respond to environ-
mental or developmental stimuli. For example, immediate tran-
scriptional changes to a new signaling cue are often restricted
to genes with active and/or poised enhancers, whereas inactive
genes with unmarked (inactive) enhancers remain refractory
(Ghisletti et al., 2010; Heintzman et al., 2009).
In reprogramming, switches in enhancer states occur very
rapidly and extensively, even before the first cell division, high-
lighting an extremely quick departure from the somatic cell
identity (Koche et al., 2011). These changes go in both direc-
tions: more than 60% of fibroblast-specific enhancers are de-
commissioned, and at least 1,000 ESC-specific enhancers are
established de novo within the first 24 hr of reprogramming
factor expression, based on loss or gain of H3K4me1/2,Cell 152, March 14, 2013 ª2013 Elsevier Inc. 1331
respectively (Figure 3). Although H3K4me1/2 on its own does not
allow one to distinguish between active and poised enhancer
states, it is likely that many of the newly marked ESC-specific
enhancers are in a poised state that will be activated at later
stages of reprogramming. Thus, extensive chromatin remodel-
ing at ESC-specific promoters and enhancers precedes the tran-
scriptional activation of many pluripotency genes.
Together, these chromatin dynamics are likely crucial for the
shutdown of the somatic expression program and the transition
toward pluripotency. During differentiation, pluripotency genes
acquire a silent state that is associated with a repressive chro-
matin environment that can include DNA methylation, histone
variants, covalent histone modifications, chromatin regulatory
proteins, and occupancy of regulatory regions by nucleosomes
(Feldman et al., 2006; Mikkelsen et al., 2008; You et al., 2011).
To activate pluripotency genes, it seems that the reprogramming
factors must surmount at least two separable obstacles:
the binding block at upstream regulatory regions (i.e., distal
enhancer and promoter elements) and a block in the transactiva-
tion of the core promoter, which prevents the assembly and acti-
vation of the RNA polymerase-II-containing basal transcription
machinery. Therefore, it may not be too surprising that the acti-
vation of pluripotency genes in reprogramming is relatively slow
and potentially requires a cascade of events. The findings
described above suggest that the formation of poised ESC-
specific enhancers early in reprogramming may be a critical first
step to orchestrate the productive engagement of the core
promoter and transcriptional activation of ESC-specific genes
later in the process when proper signals are available (Taberlay
et al., 2011). This likely requires further chromatin remodeling
and/or additional transcriptional and signaling regulators that
are unavailable early in reprogramming (for more discussion,
see the transition section below). Importantly, this epigenetic
priming does not affect all pluripotency genes early on, as
many only gain an active/poised chromatin signature at their
enhancer and promoter regions late in the process (Polo et al.,
2012; Sridharan et al., 2009) (Figure 3) (see below). Under-
standing the regulation of enhancer/promoter pairs of pluripo-
tency genes during reprogramming will be an important task
for the future and will increase our general knowledge about
the dynamics of promoter and enhancer interactions (Taberlay
et al., 2011).
Relating the extensive binding of OSK to distal sites in
unmarked, closed chromatin early in human cell reprogramming
(Soufi et al., 2012) to the epigenetic priming of many ESC-
specific enhancers early in mouse reprogramming (Koche
et al., 2011) implies that the reprogramming factors may cause
at least some of these initial epigenetic priming events directly.
To test this hypothesis, simultaneous analysis of transcription
factor binding, chromatin, and transcription states is required,
and detailed studies both in vitro and in vivo need to address
whether Oct4, Sox2, and Klf4 can indeed bind regulatory DNA
sites packaged in nucleosomes and change chromatin structure.
The ability of the reprogramming factors to engage regulatory
genomic elements in closed (silent) chromatin may be a critical
feature and may explain why OSK are such potent inducers of
pluripotency and are effective in many different somatic cell
types.1332 Cell 152, March 14, 2013 ª2013 Elsevier Inc.DNA Methylation and H3K9 Methylation Influence
Reprogramming Factor Binding
Given that OSK appear to be able to efficiently engage closed
chromatin regions already early in reprogramming, it may be
surprising that many regulatory regions bound by OSKM in the
pluripotent state are not occupied early in the process
(Soufi et al., 2012; Sridharan et al., 2009). What then are the
impediments to reprogramming factor binding and action?
DNA methylation has arisen as an important factor in restricting
early reprogramming events. ESC-specific promoters and
enhancers that gain active chromatin modifications only late in
reprogramming tend to be hypermethylated in the starting fibro-
blasts and become demethylated only late in reprogramming
(Koche et al., 2011) (Figure 3). For example, hypermethylation
of key pluripotency gene promoters, including those of Nanog
and Oct4, is observed until late in reprogramming (Mikkelsen
et al., 2008; Polo et al., 2012), suggesting that demethylation of
these promoters is a rate-limiting step. By contrast, promoters
and enhancers that already gain active chromatin marks
(H3K4me2) early in reprogramming exhibit hypomethylation
throughout the entire reprogramming process (Koche et al.,
2011) (Figure 3). Thus, DNA methylation appears to limit where
histone modification changes can occur. Furthermore, Oct4
expression can establish a nucleosome-depleted region at the
distal enhancers of OCT4 and at the proximal promoter of
NANOG in somatic cells but only if these regions are un-
methylated (You et al., 2011), indicating that DNA methylation
can prevent the recruitment of the reprogramming factors
(Figure 3D). In the case of Oct4, DNA methylation must affect
binding indirectly, as its DNA motif does not contain a CpG.
Jones and colleagues proposed that DNAmethylation in flanking
sequences may stabilize the nucleosome and prevent binding
(You et al., 2011). Similarly, binding of cMyc is inhibited by
CpG methylation within its CACGTG target site (Prendergast
and Ziff, 1991). However, the binding of other transcription
factors, such as the Klf4-related transcription factor SP1, is not
affected by DNA methylation (Harrington et al., 1988), sug-
gesting that the reprogramming factors may be differentially
affected by DNA methylation. Importantly, DNA methylation is
functionally recognized as a feature that limits reprogramming
to pluripotency because interference with Dnmt1, the enzyme
responsible for the maintenance of DNA methylation (Mikkelsen
et al., 2008), promotes iPSC formation (Table 1).
Interestingly, somatic enhancers that are inactivated quickly
upon reprogramming factor expression and are typically methyl-
ated in the pluripotent state only gain hypermethylation later in
the reprogramming process (Koche et al., 2011) (Figure 3).
Thus, both the methylation of somatic genes and the demethyla-
tion of some critical pluripotency genes appear to occur only late
in reprogramming, establishing the DNA methylation pattern
characteristic of the pluripotent state, which is in contrast
to the more gradual changes in histone modifications and
transcriptional states throughout reprogramming (Koche
et al., 2011; Polo et al., 2012). This may explain, at least in
part, why reprogramming intermediates are unstable when the
reprogramming factors are withdrawn, as DNA methylation
may be required to permanently lock in a gene expression
pattern and cell identity (Koche et al., 2011). However, it needs
to be noted that reprogramming occurs normally even upon the
genetic ablation of the de novo DNAmethyltransferases Dnmt3a
and Dnmt3b, indicating that the gain of DNA methylation in
somatic promoters and enhancers may not be essential (Pawlak
and Jaenisch, 2011) (Table 1). In any case, it will be interesting to
elucidate the mechanisms underlying these bidirectional
changes of DNA methylation late in the reprogramming process.
In addition to DNA methylation, other repressive chromatin
marks affect the ability of the reprogramming factors to engage
their target sites. Indeed, Zaret and colleagues uncovered
hundreds of large regions of megabase scale that exclude re-
programming factor binding early in human cell reprogramming
even though the same regions are bound extensively by the
factors in ESCs (Soufi et al., 2012). Although gene-poor, these
regions contain various well-known pluripotency genes such
as NANOG, SOX2, and PRDM14, and almost perfectly overlap
with regions of extended H3K9me3 in the starting fibroblasts
that are in close contact with the nuclear lamina (Soufi
et al., 2012). Importantly, during reprogramming, these broad
H3K9me3 domains are erased, consistent with their absence
in human ESCs (Hawkins et al., 2010; Soufi et al., 2012; Zhu
et al., 2013), raising the possibility that the lack of OSKM binding
in these large contiguous genomic regions early in reprogram-
ming could be caused by the presence of H3K9me3.
There is currently some debate as to whether the H3K9me3
domains arise during lineage specification or are triggered in
differentiated cells in response to specific culture conditions
in vitro (Hawkins et al., 2010; Zhu et al., 2013). Regardless,
the H3K9 methyltransferase SUV39H1 is required for the
maintenance of these H3K9me3 domains, and inhibition of
TGFb signaling lowers the H3K9me3 domain signal (Soufi
et al., 2012; Zhu et al., 2013). Notably, both the suppression of
SUV39H1 and the inhibition of TGFb signaling enhance reprog-
ramming to pluripotency (Ichida et al., 2009; Onder et al., 2012;
Soufi et al., 2012) (Table 1), and inhibition of SUV39H1/2 early
in human cell reprogramming increases the access of OSKM
to sites within H3K9me3 domains (Soufi et al., 2012). Thus,
H3K9 methylation represents a barrier to the induction of plurip-
otency, at least in part, by blocking reprogramming factor
access (Figure 2D). This conclusion is supported further by the
finding that various other H3K9 methyltransferases and H3K9
demethylases control reprogramming efficiency (Chen et al.,
2013; Onder et al., 2012; Soufi et al., 2012) (Table 1). In a fasci-
nating twist, the same regions that display a shift from a broad
H3K9me3 pattern to OSKM binding during reprogramming
encompass nearly all of the 20 hot spots of aberrant epige-
netic reprogramming, which exhibit aberrant DNA methylation
patterns in human iPSCs compared to ESCs (Lister et al.,
2011; Soufi et al., 2012). Thus, the loss of H3K9me3 from these
regions may be a very inefficient process that could additionally
be influenced by the exact culture conditions used for reprog-
ramming (Zhu et al., 2013).
Transitioning between Reprogramming Steps
An important question is what exactly the rate-limiting transition
steps at various reprogramming stages are. How do reprogram-
ming cells transition fromone step to the next? Though the field is
definingmolecules that positively and negatively influence the re-programming process (Table 1), this question is still very difficult
to address due to the inefficiency of the process. Rate-limiting
transitions are likely linked to fluctuations or inherent noise of
gene expression, chromatin state, and transcription factor bind-
ing and are further influenced by cell-cell contacts or extrinsic
signals. Single-cell gene expression studies have shown that
early reprogramming cultures and intermediate reprogramming
populations both display heterogeneity, with considerable varia-
tion in gene expression between cells (Buganim et al., 2012; Polo
et al., 2012), suggesting that stochastic gene activation events
could be an important contributor to reprogramming transitions.
Some of these expression differences are likely essential for
progression toward pluripotency, whereas others may not have
any impact on the reprogramming process or may even be inhib-
itory (Buganim et al., 2012; Polo et al., 2012).
Oct4 physically interacts with various active and repressive
chromatin complexes (Pardo et al., 2010; van den Berg et al.,
2010), raising the question of whether the activator or repressor
function of Oct4 and the other reprogramming factors is
more important for reprogramming. Recent reports in which re-
programming factors were fused to strong transcriptional activa-
tion domains (TADs) or repressor proteins indicate that activator,
but not repressor, fusions promote reprogramming (Hammachi
et al., 2012; Hirai et al., 2011; Wang et al., 2011c), suggesting
that transcriptional activation is the main action of the reprog-
ramming factors in reprogramming, and may be rate limiting.
However, not all TADs can enhance the induction of pluripo-
tency. TADs of MyoD and VP16, but not those of Mef2C and
Gata4, increase iPSC formation when fused to Oct4 (Hammachi
et al., 2012; Hirai et al., 2011, 2012; Wang et al., 2011c). Because
TADs serve as a scaffold to recruit other transcription factors,
coactivators, and specific chromatin modifiers that are required
for transcriptional activation, these findings suggest the need for
specific coregulatory proteins in pluripotency induction. In addi-
tion, a strong transcriptional activator may bypass the require-
ment for extensive chromatin remodeling at the promoter for
recruitment of the basic transcriptional machinery and preinitia-
tion complex assembly (Koutroubas et al., 2008). Of note, the
ectopic tethering of a strong transcriptional activator (the VP16
TAD) to the silent Oct4 gene in somatic cells is capable of acti-
vating this allele within 48 hr. However, this activation only
happens in a small number of cells, highlighting the need for
additional regulatory events (Hathaway et al., 2012).
Given that the reprogramming factors may act predominantly
as transcriptional activators, it may be surprising that the initial
transcriptional response includes the silencing of the somatic
expression program. However, transcriptional activators could
amplify or induce the expression of other transcriptional activa-
tors as well as repressors, which in turn could secondarily affect
gene expression patterns via emergent feedforward and feed-
back circuitries and could thereby contribute to the cell fate
change of reprogramming. High levels of strong transcription
factors may also contribute indirectly to the repression of other
genes by competing for binding at common sites on the basic
transcriptional machinery in a process referred to as squelching
(Gill and Ptashne, 1988). Additionally, not only coding genes but
also miRNAs are dynamically regulated during reprogramming
and have been implicated in the control of the reprogrammingCell 152, March 14, 2013 ª2013 Elsevier Inc. 1333
Table 1. List of Selected Chromatin Regulators and Their Role in Reprogramming
Chromatin Mark Chromatin Regulator Reprogramming Phenotype References
H3K4me Wdr5 (MLL-HMTase subunit,
H3K4me-binding protein)
required during the initial phase of reprogramming;
interacts with Oct4
Ang et al., 2011
H3K9me Suv39h1/2; Setdb1 (ESET);
Ehmt2 (G9a) (HMTases)
depletion of Suv39h1, Suv39h2, Setdb1, or
Ehmt2 results in efficient conversion of partially
reprogrammed cells to iPSCs in themouse system;
depletion of Suv39h1/2 enhances human cell
reprogramming and allows for more efficient
binding of the reprogramming factors to domains
with broad H3K9me3 in the starting cell
Chen et al., 2013; Onder et al.,
2012; Soufi et al., 2012
Kdm3/4 (demethylases) overexpression enhances reprogramming;
knockdown reduces the conversion of
partially reprogrammed cells to iPSCs
Chen et al., 2013
H3K27me PRC2 (Ezh2, Eed) (HMTase) required for reprogramming Onder et al., 2012; Buganim
et al., 2012
Utx (demethylase) interacts with reprogramming factors; required
for reprogramming; depletion results in aberrant
and inefficient resetting of H3K27me and impairs
reactivation of pluripotency genes; depletion of
Eed rescues the reprogramming defect due
to Utx loss of function
Mansour et al., 2012




(requiring the demethylase activity) by affecting the
early reprogramming phase; enhances in part by
promoting cell-cycle progression and overcoming
senescence through repression of the Ink4/Arf
locus and/or facilitating the early transcriptional
response to the reprogramming factors
Wang et al., 2011a; Liang
et al., 2012
H3K79me Dot1 (HMTase) depletion in the early phase enhances
reprogramming; inhibition results in more
efficient loss of H3K79me2 from somatic
genes, thereby promoting their downregulation;
depletion allows reprogramming without ectopic
Klf4
Onder et al., 2012
Histone
acetylation
HDACs (histone deacetylases) HDAC2 knockout allows reprogramming to be
driven by the overexpression of only microRNAs;
small-molecule inhibitors of HDACs (such as VPA,
TSA, and butyrate) enhance reprogramming and
replace ectopic cMyc or Klf4
Anokye-Danso et al., 2011;
Huangfu et al., 2008; Mali






overexpression appears to enhance binding
of Oct4 to its pluripotency targets during
reprogramming
Singhal et al., 2010
Chd1 essential for reprogramming Gaspar-Maia et al., 2009
Histone variants macroH2A deletion enhances reprogramming to pluripotency,
overexpression prevents efficient reprogramming
of EpiSCs to naı¨ve pluripotent cells; recruited to
regulatory region of pluripotency genes in mouse
embryonic fibroblasts, but not in ESCs
Pasque et al., 2012
DNA methylation Dnmt1 (maintenance
methyltransferase)
depletion enhances reprogramming of fibroblasts
and partially reprogrammed cells, similar to
5-azacytidine (5-AZA) treatment
Mikkelsen et al., 2008
Dnmt3a/b (de novo
methyltransferases)
dispensable for reprogramming Pawlak and Jaenisch, 2011
(Continued on next page)
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Table 1. Continued
Chromatin Mark Chromatin Regulator Reprogramming Phenotype References
Others OGT (O-GlcNAc
glycosyltransferase)
blocking O-GlcNAcylation impairs reprogramming;
O-GlcNAcylation regulates the transactivation
activity of Oct4 and Sox2; O-GlcNAcylation-
defective mutant of Oct4 fails to support
reprogramming
Jang et al., 2012
Parp1 (poly ADP-ribose
polymerase)
enzymatic function and DNA-binding domain are
required for reprogramming; recruited to
pluripotency genes (e.g., Nanog promoter) in the
early phase to control 5meC levels and control
Oct4 recruitment
Doege et al., 2012
Tet2 (FeII and 2-oxoglutarate-
dependent enzyme)
required for efficient reprogramming; required
for the global as well as gene-specific (e.g., at
pluripotency gene promoters) increase in
5-hydroxymethylcytosine (5hmC) mark during
reprogramming
Doege et al., 2012process, even allowing for the induction of pluripotency without
the ectopic expression of any transcription factor (Anokye-
Danso et al., 2011; Judson et al., 2009). miRNA expression
inversely correlates with target gene expression during reprog-
ramming (Polo et al., 2012), suggesting that miRNAs may be
critically contributing to the silencing of the somatic gene
expression program and subsequent reprogramming steps.
For example, an increase of miR-130 and miR-301 early in re-
programming enhances the process by repressing the develop-
mental regulator Meox2 (Pfaff et al., 2011), and miRNAs of the
miR-200 family are induced early and contribute to
the repression of the fibroblast regulators Zeb1 and Zeb2
(Samavarchi-Tehrani et al., 2010). The experimental depletion
of pre-existing lineage factors also promotes reprogramming
(Hanna et al., 2008) likely by facilitating the decommissioning
of somatic enhancers, thereby enabling the transition to the
next reprogramming stage.
What leads to the hierarchical pluripotency gene activation
late in reprogramming? As discussed before, their efficient
transcription requires the combinatorial and synergistic action
of multiple activators bound to the enhancer and/or distal
promoter. Enhancers can be modular, whereby each transcrip-
tion factor contributes to the transcriptional output, or nonmod-
ular, whereby each transcription factor is essential such that the
target gene is turned on only when all transcription factors are
present. Particularly considering that many ESC-specific
enhancers are bound by a large number of pluripotency tran-
scription factors in ESCs (Figure 2A), the presence of OSKM
alone is likely not sufficient for efficient binding and/or transacti-
vation. One of the factors that needs to act alongside OSK
appears to be the pluripotency transcription factor Nanog.
Nanog co-occupies many pluripotency genes together with
OSK in ESCs and targets promoter regions that fail to bind
OSK until the end of the reprogramming process (Sridharan
et al., 2009) (Figure 2A). Intriguingly, Nanog is essential for the
establishment of iPSCs (Silva et al., 2009) and becomes ex-
pressed before many other pluripotency genes during the
reprogramming process (Golipour et al., 2012), suggesting that
it could be required for their activation. Overexpression of Esrrb,another pluripotency factor, can rescue OSKM-induced reprog-
ramming in the absence of endogenous Nanog (Festuccia et al.,
2012). Fitting with the concept of hierarchical pluripotency acti-
vation, Esrrb is a direct target of Nanog in ESCs (Festuccia
et al., 2012). Therefore, a critical function of Nanog in reprogram-
ming may be to activate Esrrb, which in turn directly interacts
with the general transcriptional machinery and also co-occupies
many pluripotency loci with OSK and Nanog (Percharde
et al., 2012; van den Berg et al., 2010). Interestingly, a recent
RNAi screen identified various chromatin regulators, including
Morc1, as regulators of the final reprogramming steps, which
have not yet directly been implicated in the maintenance of
pluripotency (Golipour et al., 2012), indicating that in addition
to transcriptional activation an extensive chromatin remodeling
may be required at the late reprogramming stage.
Today, we are just beginning to discover how chromatin limits
but also guides reprogramming factors and how the factors
overcome chromatin barriers. Direct interactions of the reprog-
ramming factors with chromatin regulators may be important.
For example, Oct4 can interact with subunits of the BAF
chromatin-remodeling complex (Pardo et al., 2010; van den
Berg et al., 2010), which enhances reprogramming and could
stimulate the binding of transcription factors to nucleosomal
sites (Singhal et al., 2010; Utley et al., 1997). Similarly, the activity
of the reprogramming factors can be modulated by posttransla-
tional modifications such asO-GlcNAc, which in the case of Oct4
is required for activation of target genes in ESCs and for Oct4’s
full functionality in reprogramming (Jang et al., 2012).
Recent studies have identified additional chromatin regulators
that are essential for the process (for a summary, see Table 1).
For example, the H3K27me demethylase Utx also interacts
with OSK and is critical for the removal of this repressive
H3K37me3 from pluripotency loci (Mansour et al., 2012).
Similarly, decreasing the levels of histone marks associated
with transcriptional elongation promotes the downregulation
of the somatic gene expression program and suppression of
senescence regulators (Liang et al., 2012; Onder et al.,
2012; Wang et al., 2011a). While additional regulatory factors
likely need to function alongside OSKM to allow for bindingCell 152, March 14, 2013 ª2013 Elsevier Inc. 1335
Figure 4. X Chromosome States in Mouse and Human Pluripotent Cells
(A) X chromosome inactivation and reactivation cycles in the mouse system, highlighting the association of naive pluripotency with the XaXa state and of primed
pluripotency with the XiXa state. Xa, active X chromosome; Xi, inactive X chromosome.
(B) Drift and hierarchy of X chromosome states in female human ESCs during long-term culture. Xe, eroded Xi. The box marks the only X chromosome state that
allows de novo X inactivation upon induction of differentiation.
(C) Xi reactivation does not occur when female human somatic cells are reprogrammed to primed iPSCs (under bFGF reprogramming conditions). While
fibroblasts are mosaic for which X is inactivated (Xp, paternal X; Xm, maternal X), each early passage iPSC line carries the X-inactivation state of the differentiated
cell that initiated the reprogramming event. This state is subsequently maintained upon differentiation.
(D) As in (B) but for the drift and hierarchy of X chromosome states in female human iPSCs during long-term culture.to repressed pluripotency genes (Doege et al., 2012), such an
opportunity may normally arise during every cell division, imme-
diately following DNA replication before nucleosome assembly
(Wolffe, 1991). It remains to be determined whether replication
(i.e., cell proliferation) is required for changing gene expression
patterns at every stage of the reprogramming process.
X Chromosome State in Differentiation and
Reprogramming in the Mouse Model
In the remaining sections of this Review, we will focus on the
characterization of the induced pluripotent state in both mouse
and human iPSCs, highlighting differences and parallels
between these two cell types particularly as they relate to the
epigenetic state of the X chromosome. In mammals, X chromo-
some inactivation (XCI) leads to the transcriptional silencing of
one X chromosome in female (XX) cells, equalizing gene dosage
to XY males. This epigenetic process has been very powerful in
revealing that the typical reprogramming experiment with human
and mouse cells leads to different developmental states. XCI1336 Cell 152, March 14, 2013 ª2013 Elsevier Inc.involves several noncoding RNAs and a dramatic reorganization
of chromatin with various epigenetic layers of regulation such as
DNAmethylation, histone modifications, and late replication in S
phase (reviewed in Wutz [2011]). In the mouse, X chromosome
silencing is established very early in embryonic development,
in the epiblast cells of the implanting blastocyst, which will give
rise to the embryo proper. XCI can therefore be recapitulated
in vitro in differentiating mouse ESCs, the in vivo counterpart of
the epiblast cells of the preimplantation blastocyst. Differentia-
tion induces expression of the noncoding RNA Xist, which then
quickly spreads to coat the chromosome in cis, mediating
silencing of X-linked genes and inducing a repressive
chromatin character along the entire chromosome (Wutz, 2011)
(Figure 4A). This process is random such that the paternally
and maternally inherited X chromosome (Xp and Xm, respec-
tively) become silenced with equal chance. However, in the
mouse system, two states of pluripotency exist in vivo and
in vitro. ESCs and the epiblast cells of the preimplantation
blastocyst represent the naive pluripotent state. By contrast,
primed pluripotent cells are isolated from the epithelialized
epiblast of the postimplantation embryo as mouse epiblast
stem cells (EpiSC) and represent a developmentally advanced
pluripotent state (Brons et al., 2007; Tesar et al., 2007). Conse-
quently, EpiSCs are distinct from ESCs in gene expression,
growth factor dependence, morphology, and the ability to
contribute to blastocyst chimeras, although various core plurip-
otency regulators are present in both mouse ESCs and EpiSCs
and both cell types are capable of multilineage differentiation
in vitro (reviewed in Nichols and Smith [2009]). Importantly,
EpiSCs are post X-inactivation, i.e., are XiXISTXa, mirroring the
state of the epithelialized epiblast in vivo (Pasque et al., 2011)
(Figure 4A). Therefore, in the mouse system, the XaXa state
appears to be a hallmark specifically of naive pluripotency.
Because XCI represents one of the most dramatic events of
facultative heterochromatin formation in mammalian develop-
ment, the question arises of how the somatically silent X chromo-
some is regulated during reprogramming. In the mouse system,
the typical reprogramming experiment establishes naive pluripo-
tency, i.e., iPSCs that are equivalent to leukemia inhibitory factor
(LIF)-dependent, naive ESCs. Our lab demonstrated that female
mouse iPSCs, like female mouse ESCs, carry two active X chro-
mosomes (XaXa), indicating that the Xi is reactivated during
reprogramming to naive pluripotency (Maherali et al., 2007)
(Figure 4A). The activation of genes on the Xi is accompanied
by the loss of all known heterochromatic chromatin marks and
the silencing of Xist (Maherali et al., 2007). Together, these
events enable random X-inactivation upon induction of differen-
tiation, indicating that there is no epigenetic memory for the prior
Xi left behind. Xi reactivation occurs very late in the reprogram-
ming process at around the time of pluripotency gene expression
(Stadtfeld et al., 2008). In contrast to iPSCs, induced EpiSCs
(iEpiSCs) —generated by OSKM expression and culture condi-
tions required for support of the primed pluripotent state
(bFGF/activin) —are XiXISTXa (Han et al., 2011) (Figure 4A).
EpiSCs can be reprogrammed to the ESC-like state with various
transcription factors and a switch in culture environment, estab-
lishing the XaXa state (Nichols and Smith, 2009) (Figure 4A).
Together, these findings establish the X chromosome state as
a sensitive indicator of the developmental state in the mouse
system, both in differentiation and reprogramming processes,
and demonstrate that the XaXa state is indisputably only associ-
ated with the naive state of pluripotency in this system.
X Chromosome Status in Human ESCs and iPSCs
The analysis of human ESCs led to the puzzling observation that
various ESC lines differ in their X chromosome status (Hoffman
et al., 2005; Shen et al., 2008; Silva et al., 2008) (Figure 4B). (1)
They can be XaXa and undergo XCI upon differentiation, compa-
rable to mouse ESCs. (2) Some human ESC lines have already
undergone XCI and display a heterochromatic Xi with XIST
RNA coating the undifferentiated state (XiXISTXa). (3) Many
human ESCs have a silent Xi that lacks XIST expression
(Xiw/oXISTXa). Currently it is thought that newly derived human
ESCs start in the XaXa state and subsequently drift toward XCI
and later loss of XIST RNA with additional time in culture
(Figure 4B). The strongest support for this model comes from
the fact that the XaXa state can be stabilized in newly derivedESCs under physiological oxygen conditions, whereas chronic
exposure to atmospheric oxygen concentrations irreversibly
induces XCI (Lengner et al., 2010). Regardless of the X chromo-
some state, human ESCs generally share more features with the
primed pluripotent state of the mouse than with mouse ESCs
(Nichols and Smith, 2009). Therefore, the XaXa state is not
restricted to naive pluripotency in the human system and can
also mark the primed pluripotent state. To date, the occurrence
of the XaXa state and the instability of the X have not been
described for mouse EpiSCs and, in fact, for any other cell type.
Given the different states of the X in human ESCs, an inter-
esting question was whether reprogramming of female human
cells to iPSCs, which recapitulate the primed pluripotent state
of human ESCs, would result in Xi reactivation. Originally, our
group demonstrated that female human iPSC lines carry an
XISTRNA-coated Xi (XiXISTXa) when they are first derived (Tchieu
et al., 2010) (Figure 4C). In contrast to somatic cell populations,
which are mosaic with respect to which X chromosome is
inactivated, iPSC lines display a nonrandom pattern of XCI that
is maintained upon induction of differentiation (Tchieu et al.,
2010). As a result, two types of iPSC lines can be derived—those
expressing only the Xp (XmiXpa) and those expressing only the
Xm (XmaXpi) (Tchieu et al., 2010) (Figure 4C). Therefore, reprog-
ramming to human iPSCs does not elicit Xi reactivation, and
iPSCs inherit the Xi of the particular somatic cell in the culture
dish that underwent a successful reprogramming event (Pomp
et al., 2011; Tchieu et al., 2010). Although subsequent reports
confirmed this conclusion (Cheung et al., 2011; Pomp et al.,
2011), other groups obtained conflicting results and argued
that Xi reactivation is prevalent in iPSCs (Kim et al., 2011;
Marchetto et al., 2010).
Recent reports help to reconcile these apparently con-
tradictory conclusions and confirm that the silent state of the X
is faithfully maintained through the reprogramming process but
unravels with the time that iPSCs spend in culture (Anguera
et al., 2012; Mekhoubad et al., 2012; Nazor et al., 2012; Tchieu
et al., 2010; Tomoda et al., 2012). Similar to human ESCs, human
iPSCs are prone to undergo XIST silencing upon prolonged
passaging, yielding Xiw/oXISTXa lines and accordingly losing all
XIST RNA-dependent repressive chromatin marks such as
H3K27me3 (Pomp et al., 2011; Tchieu et al., 2010) (Figure 4D).
Reprogramming experiments with female fibroblasts heterozy-
gous for a mutation of the X-linked gene HPRT combined with
an elegant drug selection system that can distinguish between
the expression of wild-type or mutant HPRT revealed that spon-
taneous loss of XIST RNA coating coincides with re-expression
of the HPRT allele from the Xi (Mekhoubad et al., 2012). Thus,
XiHPRTwtXaHPRTmut iPSCs express only the mutant HPRT allele
at early passage but activate the wild-type HPRT allele upon
XIST RNA loss. Importantly, the activation of Xi-linked genes is
not limited to this one gene but appears to affect the Xi more
broadly, as demonstrated by global expression and DNA meth-
ylation profiles of female iPSC lines (Anguera et al., 2012;
Mekhoubad et al., 2012; Nazor et al., 2012). Specifically, in early
passage XiXISTXa iPSCs, X-linked genes are expressed at the
level of male (XaY) iPSCs and display DNA methylation in
promoters of Xi-linked genes (Mekhoubad et al., 2012; Nazor
et al., 2012). By contrast, higher-passage female iPSCs with noCell 152, March 14, 2013 ª2013 Elsevier Inc. 1337
XIST RNA (Xiw/oXISTXa) are often characterized by higher expres-
sion of various X-linked genes and hypomethylation of a subset
of Xi-linked promoters, suggesting that the loss of DNA methyl-
ation contributes to the activation of Xi-linked genes.
Importantly, the activation of X-linked genes does not appear
to affect the entire X chromosome. Eggan and colleagues coined
the partial reactivation of the Xi ‘‘erosion of dosage compensa-
tion,’’ yielding an eroded Xi, the Xe (Mekhoubad et al., 2012)
(Figure 4D). Even with long-term culturing, none of the female
human iPSC lines reach the low DNA methylation level along
the entire X that is typical for male iPSCs (with their single Xa),
indicating that even in the worst case the activation of genes
on the Xi is limited in range (Nazor et al., 2012). Across many
female human iPSC lines, the X chromosome is affected to
varying degrees, but the loss of DNA methylation appears to
target similar large, noncontiguous regions of the X chromo-
some, indicating that certain parts of the X can effectively main-
tain proper silencing while others are more prone to reactivation
(Nazor et al., 2012). The patchy erasure of DNA methylation
along the X, along with loss of gene silencing and XIST RNA
coating, cannot be corrected upon differentiation, nor upon
a repeated round of reprogramming (Mekhoubad et al., 2012;
Nazor et al., 2012). Together, these findings are most consistent
with amodel in which reprogramming sustains the XiXISTXa state,
but continued passaging of iPSCs results in XIST silencing
(Xiw/oXISTXa), which then triggers partial reactivation of the Xi
(Xew/oXISTXa) (Figure 4D). Notably, one could argue that these
X-related events are a consequence of continued reprogram-
ming processes, particularly given that continuous passaging
of iPSCs reduces gene expression differences compared to
ESCs (Chin et al., 2010; Polo et al., 2010). However, the erosion
of the X has also recently been observed in many human ESC
lines upon XIST RNA loss, very similar in extent to iPSCs (Nazor
et al., 2012) (Figure 4C). Importantly, iPSCs with an eroded Xi still
depend on FGF/Activin signaling to maintain pluripotency
(Mekhoubad et al., 2012), confirming that the erosion of the X
chromosome occurs in the context of primed pluripotency and
is likely not associated with a change in cell identity to naive plu-
ripotency. Thus, for human pluripotent cells (iPSCs and ESCs),
dosage compensation erosion appears to be a problem of cell
culture, particularly given that it remains a feature of the differen-
tiated progeny, necessitating the development of improved
culturing methods for these cell types (see below).
Why are XIST expression and the silent state of the X unstable
upon long-term culturing? A few relevant observations have
been made. iPSC lines obtained from the same reprogramming
experiment (i.e., the same fibroblast population) typically display
widely different X states at the same passage, with some lines
being able to maintain the XiXISTXa state and others being on
the path of erosion (Anguera et al., 2012; Kim et al., 2011;
Mekhoubad et al., 2012; Nazor et al., 2012; Tchieu et al.,
2010). Similarly, any given iPSC and ESC line can be heteroge-
neous regarding its X chromosome state (Anguera et al., 2012;
Mekhoubad et al., 2012; Silva et al., 2008; Tchieu et al., 2010;
Tomoda et al., 2012). These findings, combined with the fact
that no genomic abnormalities were found in iPSC lines with an
eroded Xi, suggest that epigenetic, but not genetic, changes
are responsible for the instability of the X chromosome (Anguera1338 Cell 152, March 14, 2013 ª2013 Elsevier Inc.et al., 2012; Mekhoubad et al., 2012). Consistently, complete
methylation of the XIST promoter correlates with the loss of the
RNA in iPSCs (Tchieu et al., 2010), implying that de novo meth-
ylation contributes to its silencing. Interestingly, in mouse fibro-
blasts, experimentally induced loss of Xist by itself does not
induce the reactivation of candidate X-linked genes (Csan-
kovszki et al., 2001). However, when Xist loss is combined with
the deletion of Dnmt1 and loss of DNA methylation, a dramatic
reactivation of the Xi occurs inmouse somatic cells (Csankovszki
et al., 2001). This parallels what happens when the Xi erodes in
human iPSCs, suggesting that deregulation of the DNA methyl-
ation machinery may directly contribute to this process.
An interesting observation is that the propagation of XiXISTXa
iPSCs in media containing bFGF and IGF2 and on feeder cells
expressing LIF predictably induces XIST RNA loss and activates
genes of the Xi after only a few passages. In this case, silencing is
reinitiated upon differentiation, suggesting that complete Xi
reactivation occurred, establishing an XaXa state in human
iPSCs, rather than an Xe (Tomoda et al., 2012) (Figure 4D).
Based on cell morphology, it appears that these XaXa cells still
maintain the primed pluripotent state (Tomoda et al., 2012). A
somewhat surprising observation is that XIST RNA was not de-
tected at the endpoint of differentiation (Tomoda et al., 2012).
More work will be needed to test whether XIST is upregulated
earlier in the differentiation process, as X inactivation without
XIST expression would be a highly unexpected possibility
(Figure 4D). In any case, this study re-emphasizes that culture
conditions can have a dramatic impact on the epigenetic state
of the X in human iPSCs and enhance transition between X chro-
mosome states.
A comparison of the X states in female human ESCs and iPSCs
highlights two key differences. The XaXa state appears to be the
most ‘‘immature’’ state for primed human ESCs (Lengner et al.,
2010) (Figure 4B, boxed), but it is a downstream state in the
hierarchy of X states in primed human iPSCs (Tomoda et al.,
2012) (Figure 4D, boxed). Hypoxic conditions or the addition of
HDAC inhibitors, which appear to promote the generation and
maintenance of XaXa hESCs (Lengner et al., 2010; Ware et al.,
2009), do not enhance the establishment of XeXa or XaXa iPSCs
(Anguera et al., 2012; Kim et al., 2011; Mekhoubad et al., 2012;
Pomp et al., 2011; Tchieu et al., 2010). One reason for the differ-
ence in X-state hierarchies between human iPSCs and ESCs
may be that the cells are of very different origin—iPSCs are
derived from somatic XiXa cells and ESCs from XaXa cells of
the female human blastocyst (Okamoto et al., 2011). Under-
standing the behavior of the human X in ESCs and iPSCs will
be an important contribution to the ongoing debate about poten-
tial transcriptional, epigenetic, and genetic differences between
various iPSC and ESC lines and their relevance (Lowry, 2012).
It is important to realize that human pluripotent cells that re-
semble the naive, mouse ESC state can be established in vitro
via transcription-factor-induced reprogramming methods. For
example, the overexpression of OCT4 and KLF4 or KLF4 and
KLF2 in primed human ESCs/iPSCs or OSKM in fibroblasts,
combined with specific culture conditions that support the naive
state, allows the establishment of human naive iPSCs (Hanna
et al., 2010). However, the naive state is still relatively difficult
to establish and maintain (Hanna et al., 2010; Pomp et al.,
Figure 5. Effects of X Chromosome Instability on Disease Modeling
Reprogramming of differentiated cells from females heterozygous for an
X-linked mutation results in iPSC lines that express either the mutant or the
wild-type allele from the Xa at early passage due to nonrandom X inactivation.
These cell lines represent pairs of experimental and control cells ideal for
modeling X-linked diseases on an isogenic background. However, upon XIST
loss and Xi erosion, the allele from the Xi can become re-expressed, resulting
in the loss or modulation of the disease phenotype.2011; Wang et al., 2011b). When derived from XiXISTXa iPSCs,
naive human pluripotent cells become XIST negative but display
XIST RNA coating in virtually all cells upon differentiation (Hanna
et al., 2010). Despite the fact that the analysis of the X chromo-
some state in naive human cells is still in its infancy, these data
argue strongly that the mouse ESC-like XaXa state, which allows
XIST-dependent induction of X inactivation during differentia-
tion, can be established in human cells upon reprogramming to
the naive state. Naive human pluripotent cells may therefore
represent an excellent model to study the regulation of human
XCI and may get around problems associated with the instability
of the X in primed pluripotent cells. However, the existence of
human naive (mouse ESC-like) pluripotent cells in vivo remains
unclear, and their derivation from preimplantation embryos has
not yet been accomplished (Kuijk et al., 2012; Roode et al.,
2012).
Instability of the Human X, Differentiation, and Disease
Modeling
iPSCs can be derived for specific diseases and can differentiate
into any cell type of the human body. Therefore, they offer an
unprecedented opportunity to examine disease states and
develop novel drugs (Onder and Daley, 2012; Trounson et al.,
2012). The nonrandom X inactivation in early passage XiXISTXa
iPSCs has an interesting consequence for the modeling of
X-linkeddiseases.Considering females heterozygous for amuta-
tion in an X-linked gene, iPSCs can be derived that express either
the wild-type or the mutant form of the protein, which represent
an interesting experimental system for the investigation of
disease phenotypes, as both wild-type and mutant cell lines
are on the same genetic background (Tchieu et al., 2010) (Fig-
ure 5). To date, X-linked diseases such as Rett syndrome and
Lesch-Nyhan syndrome (LNS) have been modeled by such
matched iPSCs (Cheung et al., 2011; Kim et al., 2011; Mekhou-
bad et al., 2012). For example, mutations in the X-linked gene
HPRT cause LNS, which leads to behavioral and neurological
symptoms in males but is typically nonsymptomatic in heterozy-
gous females because of random X inactivation (Figure 5). From
these heterozygous females, XiHPRTwtXaHPRTmut iPSCs can be
obtained that, at early passage, exhibit the LNS phenotype
upon differentiation into neurons in vitro, whereas iPSCs with
the opposite X-inactivation pattern (XiHPRTmutXaHPRTwt) behave
normally (Mekhoubad et al., 2012). However, at higher passage,
erosion of the Xi in XiHPRT wtXaHPRTmut iPSCs leads to the expres-
sion of the wild-type HPRT allele and loss of the disease pheno-
type (Mekhoubad et al., 2012) (Figure 5). The interpretation of X-
linked disease studies therefore requires caution and a careful
assessment of the X chromosome state.
Problems caused by the erosion of the Xi in human iPSCs and
ESCs do not only apply to studies of X-linked diseases but
should also be taken seriously for the modeling of autosomal
diseases or, in fact, any differentiation process, as the erosion
of the Xi in long-term culture can also alter the expression of
some autosomal genes in addition to increasing X-linked gene
expression (Anguera et al., 2012). Furthermore, female iPSC
lines without XIST expression grow faster in culture, survive
better in routine culturing, and appear to form only poorly differ-
entiating teratomas, which may be associated with the upre-gulation of several X-linked oncogenes (Anguera et al., 2012),
indicating that the erosion of the X affects the behavior of female
iPSCs and ESCs more broadly. Importantly, all recent studies
agree that loss of XIST RNA coating is closely associated with
the erosion of the Xi under conventional culture conditions
(Anguera et al., 2012; Mekhoubad et al., 2012; Nazor et al.,
2012; Tchieu et al., 2010; Tomoda et al., 2012). Thus, currently
female human iPSCs with XIST RNA coating should be preferen-
tially used for any downstream application, as these cells are in
the well-defined XiXa state. Accordingly, Lee and colleagues
proposed that XIST RNA coating of the Xi and the accumulation
of XIST-dependent chromatin marks such as H3K27me3 can be
considered biomarkers, as they appear to directly identify the
stable XiXa state (Anguera et al., 2012).
Outlook
The improved mechanistic understanding of the path to pluripo-
tency has already enabled the establishment of non-OSK-
containing reprogramming cocktails (Buganim et al., 2012;
Mansour et al., 2012) and allowed for the replacement of essen-
tial endogenous proteins by downstream targets (Festuccia
et al., 2012). Currently, we are learning only by analyzing a fewCell 152, March 14, 2013 ª2013 Elsevier Inc. 1339
snapshots of the reprogramming process. However, more and
more snapshots will eventually become a continuous epigenetic
movie of the cell fate change that underlies reprogramming to
pluripotency, through which we can virtually watch how the
epigenetic landscape is reset. The 2006 era showcased the
potency of diverse transcription factors in converting cell fates.
It now seems likely that it may eventually be possible to generate
any cell type by forced expression of the appropriate transcrip-
tion factor(s). Continued dissection of the reprogramming
process holds the promise that, at some point in the future, we
will be able to predict exactly which transcription factors are
most potent as reprogramming factors. Finally, other fields
such as tumor biologywill benefit from the insight gained through
reprogramming studies given that, for example, mutations that
prevent senescence have been shown to increase both reprog-
ramming efficiency and tumor development.
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